Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Endoscopic assisted craniosynostosis surgery experience from South-East Asia.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2020

Same author

Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins.

The Cochrane database of systematic reviews·2016

Same author

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.

The Cochrane database of systematic reviews·2015

Same author

Avoiding occlusal derangement in facial fractures: An evidence based approach.

Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India·2014

Same author

Endovascular repair of abdominal aortic aneurysm.

The Cochrane database of systematic reviews·2014

Same author

Beta blockers for peripheral arterial disease.

The Cochrane database of systematic reviews·2013

Search research articles

Related Experiment Video

Updated: Jun 29, 2026

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Beta blockers for peripheral arterial disease.

Sharath Chandra Vikram Paravastu¹, Derick Mendonca, Anthony Da Silva

¹Department of Vascular Surgery, Manchester Royal Infirmary, Oxford Road, Manchester, Lancashire, UK, M13 9WL.

The Cochrane Database of Systematic Reviews

|October 10, 2008

Summary

This summary is machine-generated.

Beta blockers do not appear to worsen walking distance for individuals with intermittent claudication. However, caution is advised due to limited large-scale trial data on beta blockers in peripheral arterial disease.

Related Experiment Videos

Last Updated: Jun 29, 2026

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Area of Science:

Cardiology
Vascular Medicine
Pharmacology

Background:

Beta blockers are standard for coronary artery disease (CAD).
Their use in patients with co-occurring intermittent claudication (IC) is debated due to potential negative effects on peripheral circulation.
This controversy stems from concerns that beta blockers may exacerbate IC symptoms.

Purpose of the Study:

To systematically evaluate the impact of beta blockers on walking capacity and peripheral hemodynamics in patients with peripheral arterial disease (PAD).
Specifically, to quantify effects on maximum walking distance, claudication distance, calf blood flow, calf vascular resistance, and skin temperature.

Main Methods:

A comprehensive search of randomized controlled trials (RCTs) was conducted using the Cochrane Peripheral Vascular Diseases Group Trials Register and CENTRAL.
Included RCTs compared selective or non-selective beta blockers against placebo in PAD patients.
Primary outcomes included walking distances and times; secondary outcomes involved calf hemodynamics and skin temperature.

Main Results:

Six RCTs involving 119 patients were analyzed, testing beta blockers like atenolol, propranolol, pindolol, and metoprolol.
No statistically significant adverse effects on walking distance or hemodynamic parameters were observed.
No adverse events related to beta blocker use were reported in the included studies.

Conclusions:

Current evidence does not support the notion that beta blockers negatively impact walking distance in individuals with intermittent claudication.
Despite the lack of evidence for harm, the limited number of large trials suggests cautious use of beta blockers when clinically indicated for PAD patients.